153 related articles for article (PubMed ID: 23649869)
1. Tumor lysis syndrome soon after treatment with hydroxyurea followed by nilotinib in two patients with chronic-phase chronic myelogenous leukemia.
Hua J; Iwaki Y; Inoue M; Hagihara M
Int J Hematol; 2013 Aug; 98(2):243-6. PubMed ID: 23649869
[TBL] [Abstract][Full Text] [Related]
2. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
[TBL] [Abstract][Full Text] [Related]
3. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Deremer DL; Ustun C; Natarajan K
Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
[TBL] [Abstract][Full Text] [Related]
4. [Chronic-phase chronic myeloid leukemia with intracranial hemorrhage complicated with tumor lysis syndrome].
Oyama C; Arakawa Y; Ikeda Y; Aoki T; Kubota Y; Isobe K; Mori M; Kurihara J; Koh K
Rinsho Ketsueki; 2021; 62(5):346-351. PubMed ID: 34108312
[TBL] [Abstract][Full Text] [Related]
5. U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission.
Pulte ED; Wroblewski T; Bloomquist E; Tang S; Farrell A; Deisseroth A; McKee AE; Pazdur R
Oncologist; 2019 May; 24(5):e188-e195. PubMed ID: 31019020
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
[TBL] [Abstract][Full Text] [Related]
7. Nilotinib therapy in chronic myelogenous leukemia.
Quintas-Cardama A; Cortes J
Drugs Today (Barc); 2007 Oct; 43(10):691-702. PubMed ID: 17987222
[TBL] [Abstract][Full Text] [Related]
8. [Nilotinib in patients with chronic myeloid leukemia without response to imatinib].
Báez-de la Fuente E; Arellano-Severiano B
Rev Med Inst Mex Seguro Soc; 2014; 52(3):330-3. PubMed ID: 24878095
[TBL] [Abstract][Full Text] [Related]
9. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
10. Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia.
Al-Kali A; Farooq S; Tfayli A
J Clin Pharm Ther; 2009 Oct; 34(5):607-10. PubMed ID: 19744017
[TBL] [Abstract][Full Text] [Related]
11. Sequential use of second-generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Kurosawa H; Tanizawa A; Muramatsu H; Tono C; Watanabe A; Shima H; Ito M; Yuza Y; Hamamoto K; Hotta N; Okada M; Saito AM; Manabe A; Mizutani S; Adachi S; Horibe K; Ishii E; Shimada H
Pediatr Blood Cancer; 2018 Dec; 65(12):e27368. PubMed ID: 30084127
[TBL] [Abstract][Full Text] [Related]
12. [Nilotinib as a second-line treatment for chronic myeloid leukemia].
Yamauchi T; Ueda T
Gan To Kagaku Ryoho; 2011 Jun; 38(6):911-5. PubMed ID: 21677481
[TBL] [Abstract][Full Text] [Related]
13. Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant.
Koren-Michowitz M; le Coutre P; Duyster J; Scheid C; Panayiotidis P; Prejzner W; Rowe JM; Schwarz M; Goldschmidt N; Nagler A
Cancer; 2010 Oct; 116(19):4564-72. PubMed ID: 20572041
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.
Quintas-Cardama A; Kantarjian H; Jones D; Nicaise C; O'Brien S; Giles F; Talpaz M; Cortes J
Blood; 2007 Jan; 109(2):497-9. PubMed ID: 16990591
[TBL] [Abstract][Full Text] [Related]
15. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.
Aichberger KJ; Herndlhofer S; Schernthaner GH; Schillinger M; Mitterbauer-Hohendanner G; Sillaber C; Valent P
Am J Hematol; 2011 Jul; 86(7):533-9. PubMed ID: 21538470
[TBL] [Abstract][Full Text] [Related]
16. Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABL.
Breccia M; Alimena G
Curr Drug Targets; 2009 Jun; 10(6):530-6. PubMed ID: 19519355
[TBL] [Abstract][Full Text] [Related]
17. Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Jarkowski A; Sweeney RP
Pharmacotherapy; 2008 Nov; 28(11):1374-82. PubMed ID: 18956997
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase inhibitor therapy prescribed for non-urologic diseases can modify PSA titers in urology patients.
Sasaki T; Franco OE; Ohishi K; Filipovich Y; Ishii K; Crawford SE; Takahashi N; Katayama N; Sugimura Y; Hayward SW
Prostate; 2019 Feb; 79(3):259-264. PubMed ID: 30370673
[TBL] [Abstract][Full Text] [Related]
19. Pathological findings suggesting vascular endothelial damage in multiple organs in chronic myelogenous leukemia patients on long-term tyrosine kinase inhibitor therapy.
Seki Y; Nagano O; Koda R; Morita S; Hasegawa G
Int J Hematol; 2020 Oct; 112(4):584-591. PubMed ID: 32557125
[TBL] [Abstract][Full Text] [Related]
20. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]